OriginCell Posts Positive Data from Trial of GPC3 CAR-T for HCC

Shanghai OriginCell Therapeutics presented positive data from an on-going trial of its GPC3 CAR-T cell therapy in patients with relapsed/refractory hepatocellular carcinoma (HCC). Ori-CAR-001 produced a 44.4% objective response rate and a 77.8% disease control rate in the eleven enrolled patients, all of whom had received two previous treatments. OriginCell has built four technology platforms, including an antibody development platform, a high-memory CAR T technology platform, a cell expansion platform and a universal CAR-T platform. OriginCell is aiming Ori-CAR-001 at solid tumor cancers. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.